Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) recently announced the granting of non-qualified stock options for 100,000 shares and restricted stock units (RSUs) for 50,000 shares to a newly hired employee. This issuance is part of the 2020 Inducement Equity Incentive Plan, effective June 21, 2022. The options have an exercise price of $4.61, matching the stock's closing price on the effective date. The vesting schedule for the options and RSUs spans four years with a combination of annual and monthly vesting milestones.
PacBio will present at the BofA Securities 2022 Healthcare Conference on May 12 at 11:20 a.m. PT. The presentation will be available via live webcast on their investors page, with a replay for 30 days post-event. The conference takes place in Las Vegas, Nevada.
PacBio, traded under the symbol PACB, focuses on advanced sequencing technologies to aid scientists in addressing complex genetic issues. Their offerings include HiFi long read and SBB short read sequencing, applicable in various research areas such as oncology and infectious diseases.
PacBio (NASDAQ: PACB) reported a 14% increase in revenue for the first quarter of 2022, totaling $33.2 million, compared to $29.0 million in Q1 2021. The company delivered a record 50 Sequel II/IIe systems, increasing their installed base to 424 systems. Gross profit rose 9% to $14.2 million, with a gross margin of 43%. However, operating expenses surged to $91.7 million, leading to a net loss of $81.5 million, a slight improvement from a net loss of $87.4 million in the previous year.
PacBio (NASDAQ: PACB) has expanded its collaboration with Children’s Mercy Kansas City to utilize its Sequel IIe system for genetic disease research. The partnership aims to apply advanced sequencing methods, including direct methylation detection and Iso-Seq™ full-length RNA sequencing, to enhance understanding and diagnosis of rare diseases. Since 2020, Children’s Mercy has sequenced nearly 1,000 samples with PacBio's technology. Recent advancements allow for integrated analyses of DNA and its function, potentially improving diagnostic yield for unsolved cases.
PacBio (NASDAQ: PACB) has announced significant advancements in its Sequel II/IIe platform, enabling DNA methylation calling in native DNA and faster sample preparation. These enhancements provide access to the epigenome without additional costs or complexity, unlocking new research opportunities. The update also simplifies workflows, reducing preparation time by over 50% and required DNA inputs by 40%. With new features supporting gene therapy applications, the enhancements aim to improve the quality and depth of genomic insights for researchers.
PacBio (NASDAQ: PACB) will host its first-quarter 2022 financial results conference call on May 4, 2022, at 5:00 pm Eastern Time. The call will be accessible via webcast on the company's website. PacBio specializes in long-read sequencing technology, enhancing genomic research through its innovative instruments. This technology enables comprehensive analysis of genomes, transcriptomes, and epigenomes, thus significantly contributing to various scientific fields including human biomedical research and microbiology.
PacBio (NASDAQ: PACB) announced a collaboration with Corteva Agriscience to advance plant biotechnology using high-throughput whole genome HiFi sequencing. This partnership aims to develop custom workflows for sequencing plant, pest, and microbial samples, enhancing DNA extraction and library preparation processes. The initiative is essential for addressing agricultural demands amid population growth. The initial phase, scheduled for completion in Q3 2022, focuses on scalable workflows to support extensive DNA sample collections from Corteva.
PacBio announces its significant role in completing the first truly complete human reference genome, as detailed in a publication from the Telomere-to-Telomere (T2T) Consortium in Science. This achievement utilized HiFi sequencing technology to assembly all three billion base pairs across 23 chromosomes, covering previously inaccessible regions. The T2T-CHM13 reference genome introduces nearly 200 million base pairs of novel sequences, improving studies on genetic diseases such as FSHD. The success of this assembly is expected to drive genomic discoveries and better understand human health.
PacBio (NASDAQ: PACB) has announced the establishment of a new European headquarters in London, set to open on April 4, 2022, aimed at addressing the growing customer demand in the EMEA region. Additionally, the company has partnered with Genesupport, the first commercial service provider to offer PacBio sequencing services in Europe. This strategic expansion is designed to enhance commercial support and collaboration for laboratories utilizing PacBio's HiFi sequencing technology. The new headquarters will include extensive lab space for customer training and development projects.
PacBio has partnered with SickKids in Toronto to use HiFi whole genome sequencing (HiFi WGS) to find genetic variants linked to medical conditions. Despite advancements in genetic testing, over 50% of cases remain undiagnosed. HiFi WGS will analyze samples from patients with suspected genetic conditions, such as autism and congenital diseases. The technology aims to uncover previously unidentified genomic variants. This collaboration represents an important step in genetic disease research, potentially enhancing detection capabilities.